Case 1:04-cv-00833-KAJ
Document 80
Filed 08/05/2005
Page 1 of 1
MORRIS, NICHOLS, ARSHT & TUNNELL
1201 N O R T H M A R K E T S T R E E T P.O. B O X 1347 W ILM IN G T O N , D E L AW AR E 19899-1347 302 658 9200 302 658 3989 F AX
M AR Y E L LE N N O R E IK A 302-575-7278
M N O R E I K A @ M N AT . C O M
August 5, 2005
BY E-MAIL The Honorable Kent A. Jordan United States District Court 844 King Street Wilmington, DE 19801 Re: Dear Judge Jordan: We write to respond briefly to Sicor's August 5th letter to the Court. Pharmacia's amended initial disclosures do not in any way suggest that Pharmacia intends to present evidence that has not been fully vetted through discovery. To the contrary, the amended disclosures merely seek to preserve Pharmacia's right to use whatever discovery may result from Sicor's discovery efforts. Reviewed in context, the statement cited by Sicor clearly refers to the following passage explicitly set forth in the document: To the extent that Sicor is permitted to take discovery from the inventors, Pharmacia may use that testimony to support its claims. This acknowledgement of standard practice is fully consistent with the positions taken in the motion papers regarding discovery pursuant to the Hague Convention and should be non-controversial. Respectfully, /s/ Maryellen Noreika Maryellen Noreika MN/bls cc: John G. Day, Esquire (By Fax) Pharmacia & Upjohn Company v. Sicor, Inc. and Sicor Pharmaceuticals, Inc., C.A. No. 04-833 (KAJ)